Marylore Chenel, Ph.D.

Chief Research Officer


  • Joined Pharmetheus in 2021, serving as Chief Research Officer, part of the executive leadership team, and leading the PBPK-QSP Business Development Platform
  • Expertise includes model-informed drug development, clinical pharmacology and regulatory advices in therapeutic areas such as oncology/immuno-oncology, immuno-inflammation, cardiology, and diabetes
  • Previously worked as Head of Global Pharmacometrics and Clinical Pharmacokinetics at Servier, France, where she led a team supporting the drug development portfolio from research to submission including lifecycle management, as Head and Deputy Head of Clinical Pharmacometrics and Clinical Pharmacokinetics, as a Pharmacometrician at Servier, France, and as Postdoctoral Fellow at the University of Manchester, UK
  • PharmD (2000) and M.Sc. in Pharmacokinetics (2000) from the University of Paris V, France, and Ph.D in Pharmacokinetics – PKPD modeling from the University of Poitiers, France
LinkedInGoogle Scholar

Pharmetheus affiliated publications

Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteersPredicting disease effect on the pharmacokinetics (PK) of sustained and immediate release formulations by applying physiologically based pharmacokinetic (PBPK) modellingPhysiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive childrenA platform for mechanistic modelling of subcutaneous administration with the effect of immunogenicity within the Open Systems Pharmacology frameworkPhysiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitisMechanistic modelling of bioavailability and local immunogenicity after subcutaneous administration within the Open Systems Pharmacology frameworkVirtual patients, digital twins and causal disease models: Paving the ground for in silico clinical trialsHow to Successfully Generate an Alternative Approach to a Thorough QT Study: GLPG1972 as an ExampleModeling Restoration of Gefitinib Efficacy by Co-Administration of MET Inhibitors in an EGFR Inhibitor-Resistant NSCLC Xenograft Model: A Tumor-in-Host DEB-Based ApproachMechanistic Modeling of the Interplay Between Host Immune System, IL-7 and UCART19 Allogeneic CAR-T Cells in Adult B-cell Acute Lymphoblastic Leukemia